Association Between Trough Level of Tacrolimus and Change in Estimated Glomerular Filtration Rate 1 Year After Living Donor Liver Transplantation.
Journal
Annals of transplantation
ISSN: 2329-0358
Titre abrégé: Ann Transplant
Pays: United States
ID NLM: 9802544
Informations de publication
Date de publication:
09 Feb 2021
09 Feb 2021
Historique:
entrez:
9
2
2021
pubmed:
10
2
2021
medline:
28
10
2021
Statut:
epublish
Résumé
BACKGROUND Although the risk factors for chronic kidney disease progression after deceased donor liver transplantation have been widely reported, there are few reports describing the factors associated with kidney function changes in patients after living donor liver transplantation (LDLT). This study aims to further investigate these kidney function change factors. MATERIAL AND METHODS This retrospective study was performed using the data of patients who underwent LDLT at the Nagasaki University Hospital, Japan from August 2000 to November 2017. Factors contributing to post-transplantation estimated glomerular filtration rate (eGFR) changes were analyzed. RESULTS A total of 191 cases were reviewed. The average age was 53.8 years, and 108 (56.5%) patients were male. Compared to pre-transplantation eGFR levels, eGFR 1 year after LDLT improved in 65 patients (34%) and deteriorated in 126 patients (66%). Multivariate regression analysis revealed that pre-transplant diuretics (P=0.04) and tacrolimus trough value 1 year after transplantation (P=0.04) were significantly associated with elevated eGFR changes. eGFR elevation 1 year after LDLT was more pronounced in patients with a low tacrolimus trough level 1 year after LDLT (P=0.01). Therefore, mycophenolate mofetil was added to tacrolimus in patients with poor renal function before LDLT. CONCLUSIONS Tacrolimus trough level was associated with eGFR changes 1 year after LDLT. The adjusted dose of tacrolimus and combined use of other immunosuppressants may be important to maintain renal function after LDLT.
Identifiants
pubmed: 33558451
pii: 928858
doi: 10.12659/AOT.928858
pmc: PMC7883405
doi:
Substances chimiques
Immunosuppressive Agents
0
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e928858Références
Exp Ther Med. 2018 Apr;15(4):3589-3595
pubmed: 29545888
J Hepatol. 2017 Oct;67(4):874-875
pubmed: 28844409
Surg Today. 2008;38(9):795-800
pubmed: 18751944
Transplant Direct. 2016 Jul 22;2(8):e94
pubmed: 27819035
Clin Exp Nephrol. 2007 Mar;11(1):41-50
pubmed: 17384997
Ann Transplant. 2020 Sep 08;25:e924805
pubmed: 32895363
Ann Surg. 2019 Jan;269(1):20-27
pubmed: 29303806
Clin J Am Soc Nephrol. 2011 Aug;6(8):1851-7
pubmed: 21784823
Clin Transplant. 2013 Jan-Feb;27(1):90-7
pubmed: 22938398
J Transplant. 2018 Dec 23;2018:5910372
pubmed: 30675397
J Clin Exp Hepatol. 2013 Sep;3(3):243-53
pubmed: 25755506
Am J Transplant. 2020 Jan;20 Suppl s1:193-299
pubmed: 31898413
Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508
pubmed: 19218475
Clin Transplant. 2016 May;30(5):518-27
pubmed: 26865166
Transplant Proc. 2018 Dec;50(10):3615-3620
pubmed: 30577246
Nephrol Dial Transplant. 2006 Sep;21(9):2630-6
pubmed: 16735393
JAMA. 2014 Jun 25;311(24):2518-2531
pubmed: 24892770